Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-10 | 2024-03 | -3.59 | -2.02 | 1.57 | 43.73% |
2024-03-22 | 2023-12 | -3 | N/A | N/A | N/A |
2023-11-13 | 2023-09 | -3.15 | -2.85 | 0.3 | 9.52% |
2023-08-11 | 2023-06 | -4.2 | -3 | 1.2 | 28.57% |
2023-05-11 | 2023-03 | -3.75 | -4.2 | -0.45 | -12.00% |
2023-03-22 | 2022-12 | -4.2 | -3.6 | 0.6 | 14.29% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-04-17 | Roth MKM | Upgrade | Buy | |
2023-03-23 | Oppenheimer | Upgrade | Outperform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-12-25 | FOSTER JONATHAN P. | Chief Financial Officer | 80.56K | Purchase |
2023-12-25 | GEORGE ROBERT E | Director | 14.66K | Purchase |
2023-12-25 | KLEMP WALTER V | Chief Executive Officer | 680.88K | Purchase |
2017-05-04 | NORTHCUT JACQUELINE | Director | 1000 | Purchase |
2023-06-19 | PICKER DONALD H | Officer | 90.01K | Conversion of Exercise of derivative security |
2017-08-15 | PRIEBE WALDEMAR PH.D. | Beneficial Owner of more than 10% of a Class of Security | 2.78M | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 1.08M | 625.17K | 3.62% |
2023-06-29 | Sio Capital Management, LLC | 303.39K | 175.60K | 1.02% |
2023-06-29 | Geode Capital Management, LLC | 246.45K | 142.65K | 0.83% |
2023-06-29 | Blackrock Inc. | 196.20K | 113.56K | 0.66% |
2023-06-29 | Renaissance Technologies, LLC | 127.40K | 73.74K | 0.43% |
2023-06-29 | Squarepoint Ops LLC | 77.24K | 44.71K | 0.26% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 616.11K | 356.60K | 2.07% |
2023-06-29 | Vanguard Extended Market Index Fund | 454.71K | 263.18K | 1.53% |
2023-05-30 | Fidelity Extended Market Index Fund | 141.91K | 89.90K | 0.48% |
2023-05-30 | Fidelity Series Total Market Index Fund | 33.89K | 21.47K | 0.11% |
2023-05-30 | Fidelity Total Market Index Fund | 30.82K | 19.52K | 0.10% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 15.56K | 9.86K | 0.05% |
Split | Date |
---|---|
1 : 15 | 2024-03-22 |
1 : 6 | 2021-02-01 |
-
-
Much better strategy at conference today on scope, timing, cash conservation and ROI…I like this approach for potential high percentage outcome that makes sense on priority managing the selected high value target as mentioned by the CFO. The value proposition was clearly stated if you understand investment banking lingo. I’m happy now!
-
50% bigger boat but we’re all re-leveled at .65-.69 regardless of old or new $. More importantly is the insider executive team finally ponying up real $ plus the single investor. Since no obvious emergency exists for currently known plans, the funds use will be interesting. I see it as encouraging development.
-
Monday eod
-
VEDU Announces New Business Development and Management Team Changes
NEWS PROVIDED BY
Visionary Education Technology Holdings Group Inc. (https://www.prnewswire.com/news/visionary-education-technology-holdings-group-inc./)
21 Sep, 2023, 08:00 ETTORONTO, Sept. 21, 2023 /PRNewswire/ -- Visionary Education Technology Holdings Group Inc. (the "Company") (NASDAQ: VEDU), a private education provider located in Canada, with subsidiaries in Canada and market partners in China, today announced the Company has decided to diversify its business into three sectors: Education, Life Sciences, and Artificial Intelligence. In addition, the Board has appointed Mr. Charlie Penn as our Chief Operating Officer, effective September 14, 2023.
The global recovery from the pandemic has spurred some economic growth, especially in the education sector. This growth demands higher efficacy and efficiency in education and training, particularly with the use of the latest Artificial Intelligence ("AI") technology for better life quality and living style. Therefore, the company is expanding its business to reflect its focus on the new generation of Education, AI and Life Science, including the expansion into life sciences for a future synergy from those exciting breakthroughs in technology. The wide-ranging integration of AI into nearly every market sector has sparked a significant demand for the corresponding educational components required to fully leverage this advanced technology. The Company, already a leader in the education sector, will now participate in the massive task of educating the global community to work in parallel with the latest AI developments. This initiative, demanding heightened efficacy and efficiency in education and training, is set to elevate the quality of life and lifestyle for populations around the world.
The Board has appointed Mr. Charlie Penn to serve as the Company's Chief Operating Officer due to his extensive investment and education management experience. In 1999, he invested in Canada Princeton College and served as an executive director. He led the management upgrade of the college from being registered by the BC PCTIA to being recognized as a college accreditation, offering Pre-University English, Business Diploma, and University credit transfer courses. A large number of international students enrolled in multiple Canadian and US universities after completing the college's English and Pre-University courses. Mr. Penn presided over the signing of distance education cooperation agreements with Lincoln University, Central University, and City University in the United States, offering MBA/BBA distance education classrooms, and organizing course exams and graduation ceremonies for American universities at the college in British Columbia. Mr. Charlie Penn also engaged in industrial real estate investment in 2007 and served as the Executive Director of Birmingham Holdings (Hong Kong Main Board Listed Companies stock code 02309) and the Executive Director of English Premier League Football Club in 2013, responsible for the management of the listed company's business and sports real estate operations. Mr. Penn earned two diplomas in Administration and Computer Applications, and also completed a Master's level program in Political Economy from Peking University through on-the-job education.
Ms. Fan Zhou, Chief Executive Officer and Chairman of the Board of the Company, commented: "We are excited to welcome Mr. Charlie Penn to the Company, Mr. Penn's rich experience in education and investment management will bring deep and valuable vision to guide the Company to the next level of success. I look forward to working closely with him."
About Visionary Education Technology Holdings Group Inc.
Visionary Education Technology Holdings Group Inc., headquartered in Toronto, Canada, is a private education provider located in Canada, with subsidiaries in Canada and market partners in China, that offers high-quality education resources to students around the globe. The Company aims to provide access to secondary, college, undergraduate and graduate and vocational education to students in Canada through technological innovation so that more people can learn, grow and succeed to their full potential. As a fully integrated provider of educational programs and services in Canada, the Company has been serving and will continue to serve both Canadian and international students. For more information, visit the Company's website at https://ir.visiongroupca.com/ (https://ir.visiongroupca.com/).
Forward-Looking Statements
All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "believes," "expects," "anticipates," "estimates," "intends," "would," "continue," "should," "may," or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors
that may affect its future results in the Company's registration statement and in its other filings with the SEC.For
-
Shorts are back after covering their positions to allow shareholders of record to vote.
-
No!!!!!!!
-
I just voted hell no to the reverse split proposal. It’s not a stock gimmick issue but a management issue we haven’t already pivoted into Phase 3. Mgmt recently pulled a fast one by reducing voting power from majority down to 1/3 of eligible voters to have a quorum - this means the deciders could be in the hands of under 10m share holders rather than the previous number of approx 15m back in June. It’s worse, the rs has increased max from 1:8 to 1:20 since June - to even water down your power even more. If you want to see how their sister company, CNS Pharmaceuticals (CNSP) has done in a similar situation last year of using a r/s of 1:30, just look at where they are now after their rs in November last year. Don’t give MBRX mgmt a license to steal you investment and draw the line now. I suspect they think with the above they have it already in the bag and next week’s special meeting is just for show. I have a lot of shares and unlike in June, nobody has called me daily to try and get me to vote and as i remember they retained services to do that if needed.
-
It’s taken a week but I will finally have 100% of my large, LONG position available for voting tomorrow morning. My broker is transmitting a batch update to ProxyVote.com tonight which has been verified to be correct. Be sure you look carefully at the proxy sheet for number of shares you own before voting. The formal explanation to why I had zero shares to vote last week was a technical’ glitch affecting many others holding MBRX. Maybe, but I remain skeptical.
-
FYI, I was informed today by ML there is a ‘technical’ glitch connecting their proxy system to their portfolio system specifically affecting MBRX shareholders by showing 0 shares available for voting regardless of shares owned. They expect to have the problem resolved shortly and will be informing me as to how/when I will be able to vote before 10/2. I do find this odd but won’t elaborate at this time.
-
Exactly 3G Cardio
-
Got my proxy material today from ML. Went to vote online and it said ‘0’ shares available to vote. I looked more carefully at the ML proxy statement and it too said 0. I checked my brokerage account and I still shows my thousands of shares correctly. Anyone else having this issue with ML?
-
Yes and the SEC now should have no problem granting any listing issues extension until illegal naked short impact has been resolved. Any r/s discussion should be tabled and energy should be focused on core trials
-
Ok Wally, this upcoming refried attempt of the earlier reverse stock proposal with new quorum rules you snuck in still won’t fly with me. I would suggest you use the remaining two months to the SEC checkpoint to focus on results oriented endeavors rather than smoke and mirrors because I’m beginning to think this is a management issue needing resolution rather than the science itself. I hope you quickly implement a plan b.
-
Too many balls in the air causing jack of all trades master of nothing—-may work out but not the way I would have done it. Better to get the prime lead trial to early pivotal to ensure a cash cow and investor confidence and your first rule of business. Now we’ve just playing games over next few months to year unnecessarily while we listen to stale re-runs. Should have had twice the trials on the lung indication even if he used the available sizable LOC until they didn’t renew and that alone raised concern as to why didn’t they?
-
Most significant is abstaining no longer registers as a no vote on most matters like in last proxy joke…see the greedy game to push their agenda now? If these rules were in place in last proxy vote, their dumb r/s would have passed.
-
When it pivots into pha 3 trial for one or more indications- that’s when ! Should already be in that position if not for this mgmt team with too many balls in the air. Not enough clinical sites in play for any one Indication especially with the now too often used cliche of no toxicity - we get I now get on with the efficacy demonstration on an expedited basis. I you’re not on the FDA’s calendar discussing pivotal plans, I have no interest in quarterly updates on trials-pretty boring and thus the sp.
-
Yawn yawn yawn
-
-
MBRX Stock Earnings: Moleculin Biotech Beats EPS for Q1 2024
news.google.com • -
Moleculin Biotech Secures Patent for Liposomal Drug Innovation- TipRanks
news.google.com • -
MBRX Stock Earnings: Moleculin Biotech Reported Results for Q4 2023
news.google.com • -
Moleculin reports 62% remission rate in AML trial with Annamycin
news.google.com • -
Moleculin Biotech Shares Corporate Update Online- TipRanks
news.google.com • -
Moleculin Biotech Shares Upbeat Annamycin AML Trial Update- TipRanks
news.google.com • -
Moleculin Biotech, Inc. (MBRX) Q4 2023 Earnings Call Transcript
seekingalpha.com • -
Moleculin to Present at the 36th Annual ROTH Conference
prnewswire.com • -
Why Is Moleculin Biotech (MBRX) Stock Is Moving Today?
investorplace.com • -
Moleculin Biotech, Inc. (MBRX) Q2 2023 Earnings Call Transcript
seekingalpha.com • -
Moleculin Biotech, Inc. (MBRX) Q1 2023 Earnings Call Transcript
seekingalpha.com • -
MBRX Stock Earnings: Moleculin Biotech Misses EPS Estimates
investorplace.com • -
Moleculin Biotech, Inc. (MBRX) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
Moleculin to Present at the H.C. Wainwright BioConnect Conference
prnewswire.com • -
MBRX Stock: Why It Increased Today
pulse2.com • -
Moleculin Announces Inclusion in the Russell 2000® Index
prnewswire.com • -
Moleculin Biotech to Present at the Q2 Virtual Investor Summit
prnewswire.com • -
MBRX Stock: Over 10% Pre-Market Explanation
pulse2.com • -
Moleculin Announces Proposed Underwritten Public Offering
prnewswire.com • -
Moleculin Announces Reverse Stock Split
prnewswire.com • -
Moleculin Biotech (MBRX) Jumps: Stock Rises 8.5%
zacks.com • -
MBRX Stock: Why Moleculin Biotech Is Soaring 21% Today
investorplace.com • -
Moleculin Biotech (MBRX) Investor Presentation - Slideshow
seekingalpha.com • -
Moleculin Pops 33% On Anti-Viral Activity For Potential Covid-19 Treatment
finance.yahoo.com • -
Moleculin Shares Jump on Progress With Virus-Drug Candidate
finance.yahoo.com • -
Moleculin Biotech (NASDAQ:MBRX) Shares Gap Down to $1.07
thelincolnianonline.com • -
Moleculin Surges on Manufacturing Deal for Coronavirus Therapy
finance.yahoo.com • -
Is Moleculin Biotech (MBRX) Outperforming Other Medical Stocks This Year?
finance.yahoo.com • -
Moleculin Provides Update on Annamycin Clinical Development
finance.yahoo.com • -
Moleculin Biotech, Inc. (MBRX) Stock Sinks As Market Gains: What You Should Know
finance.yahoo.com •